Latest Breaking News On - Timber pharmaceuticals inc - Page 13 : comparemela.com

Timber Pharmaceuticals (TMBR) Announces $1 3 Million Registered Direct Offering

Timber Pharmaceuticals (TMBR) Announces $1 3 Million Registered Direct Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCommission onExchange commissionTimber pharmaceuticals incHc wainwright coWall streetTimber pharmaceuticalsCommon stockSeriesb mirroring preferred stockSeriesb preferred stockSeriesb preferredCurrent reportPreferred stockSecurities act

Timber Pharmaceuticals Inc (TMBR) Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis

Timber Pharmaceuticals Inc (TMBR) Receives Positive Opinion on Orphan Designation from European Medicines Agency for TMB-001 for Treatment of Autosomal Recessive Congenital Ichthyosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohn koconisCommittee for orphan medicinal productsEuropean unionEuropean medicines agencyEuropean commissionDrug administrationTimber pharmaceuticals incWall streetOrphan medicinal productsChief executive officer

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study Results in Multiple Presentations at 31st EADV Congress

Press release content from NewMediaWire. The AP news staff was not involved in its creation.

United statesUniversity of pennsylvaniaAdam daleyChristopherg bunickJoyce mc tengLeslie castelo soccioJohn koconisAlanm mendelsohnEuropean academy of dermatologySchool of medicineTimber pharmaceuticalsPerelman school of medicineExchange commissionCompany annual report on formUniversity of new south walesBerry company public relations

Timber Pharmaceuticals to Highlight Phase 2b CONTROL Study

- Company announces positive clinical data of FDA-Designated Breakthrough Therapy TMB-001 demonstrating safety, efficacy and quality of life improvements.

United statesUniversity of pennsylvaniaAdam daleyChristopherg bunickJoyce mc tengLeslie castelo soccioJohn koconisAlanm mendelsohnEuropean academy of dermatologySchool of medicineTimber pharmaceuticalsPerelman school of medicineExchange commissionCompany annual report on formUniversity of new south walesBerry company public relations

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology

Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology - read this article along with other careers information, tips and advice on BioSpace

United statesAlan mendelsohnAdam daleyJoyce mc tengJohn koconisExchange commissionCompany annual report on formBerry company public relationsSecurities exchangeTimber pharmaceuticals incStanford universityJournal of the american academy dermatologyTimber pharmaceuticalsAmerican academyChief medical officerVisual index